News for Ecofibre Limited (EOF.AX)

Feb 19, 2025 / 12:00AM GMTOperator Thank you for standing by and welcome to the Ecofibre Limited first-half 2025 half-year results presentation. (Operator Instr

Ecofibre (ASX: EOF) has secured its second deal with global sportswear brand Under Armour to supply Neolast yarns to nominated knitting mills for the

Aussie markets have somehow pulled of a miracle gain despite two horror sessions this week.

There hasn’t been much change today. The market plunged and has hovered around 1.1% down ever since, in a sombre end for the week.

Feb 23, 2024 / 12:00AM GMTOperator Good day, and welcome to the Ecofibre Limited first-half '24 results presentation. Today, we will begin with the presentation

The Bank of Guam, which is a US territory, announced it would  introduce banking services tailored to the cannabis industry in Guam and the Northern Marianas, marking a significant step forward in the region's financial services for Cannabis-Related Businesses (CRBs).

The ASX200 has closed up about .4 of a per cent, with just energy, IT, industrials and utilities falling into negative territory.

The ASX 200 managed to scrape back into the green just before close today – to end the day at 7410.4 points.

The ASX has opened sharply lower on Friday, tumbling down by around one and a half per cent and at times dipping even more

Ecofibre (ASX:EOF) has established biotech entity EOF-BIO LLC to commercialise patents for its treatment of Ovarian Cancer and Endometriosis.

The ASX is set to drop for a third straight session, following a wilt on Wall Street. There are growing fears from investors another rate hike looms in the US.

New studies have confirmed that medical cannabis helps relieve cancer pain, or side effects from cancer treatment.

The date April 20th has become an unofficial holiday among cannabis enthusiasts who now call it the World Marijuana Day.

Research finds finds most Australians are still medicating with illicit cannabis, although numbers accessing legal prescription have risen.

Melbourne-based Avecho Biotechnology (ASX: AVE) is seeking to raise $11 million to fund a pivotal clinical trial evaluating the use of its cannabinoid (CBD) soft-gel capsule to treat insomnia.

The first of new products is set to be delivered by the end of FY23.

The ASX has bounced back like the little Aussie battler it is, and Besra Gold's (ASX:BEZ) leading the charge with a 75% leap for the stars.

The ASX opened lower this morning thanks to the Credit Suisse emergency, but Aussie goldies stepped up to the plate so it's not a total loss.

“In terms of stability, not all products containing CBD are created equal, and quality control can be a problem,” BOD MD Jo Patterson said.